Avance Biosciences will once again be exhibiting at the World Vaccine Congress taking place March 31 – April2, 2026 in Washington, DC, one of the premier global events dedicated to vaccine research, development, and manufacturing. The meeting brings together leaders from biotechnology companies, pharmaceutical organizations, and research institutions to discuss advances in vaccine technologies and strategies for addressing emerging infectious diseases.
As a leading CRO and contract testing laboratory supporting biologics and advanced therapies, Avance Biosciences provides specialized analytical services designed to accelerate vaccine development programs from early research through clinical development and regulatory submission. Our team will be available throughout the conference to discuss how our GLP, GMP, and CLIA-compliant testing services can support vaccine developers working with traditional platforms as well as next-generation modalities such as RNA therapeutics and mRNA vaccines.
Potency Assay Development and Validation for Vaccines
Potency assays are one of the most critical analytical components in vaccine development. Regulatory agencies require well-characterized potency assays to demonstrate that a vaccine product consistently delivers the intended biological activity.
Avance Biosciences provides custom potency assay development and validation services for vaccine programs, including cell-based assays designed to measure functional immune responses and antigen activity. Our scientists work closely with sponsors to design assays that accurately reflect the mechanism of action of the vaccine while meeting regulatory expectations for precision, reproducibility, and robustness.
These assays can be developed for a wide range of vaccine platforms, including mRNA vaccines, viral vector vaccines, recombinant protein vaccines, and DNA-based vaccines. Our capabilities include assay optimization, qualification, and full validation to support IND, BLA, and global regulatory submissions.
Specialized Testing Services for RNA Therapeutics and mRNA Vaccines
RNA therapeutics and mRNA vaccines have rapidly emerged as powerful platforms for addressing infectious diseases, cancer immunotherapy, and personalized medicine. However, the development of RNA-based vaccines requires specialized analytical approaches to ensure product integrity, sequence accuracy, and safety.
Avance Biosciences provides a comprehensive suite of next-generation sequencing and molecular testing services specifically designed to support RNA therapeutic and mRNA vaccine programs.
RNA Sequence Verification and Integrity Analysis
Our sequencing team performs high-resolution RNA sequence analysis to confirm the accuracy of vaccine constructs and detect sequence variants that could affect efficacy or safety. Using multiple sequencing platforms, we can evaluate RNA integrity, confirm coding regions, and assess structural features relevant to vaccine performance.
Next-Generation Sequencing for Quality and Safety Testing
Our NGS Center of Excellence supports vaccine developers with advanced sequencing workflows used to characterize vaccine constructs and detect potential contaminants. These services include:
- Whole genome sequencing and targeted sequencing
- Metagenomic testing for adventitious agents
- Vector and plasmid sequence confirmation
- Integration and genome interaction analysis
These approaches provide the sensitivity and depth required for comprehensive safety testing and regulatory documentation.
Bioinformatics and Data Interpretation
Avance Biosciences provides expert bioinformatics analysis and reporting, enabling clients to translate complex sequencing data into actionable insights. Our data processing pipelines are designed to meet 21 CFR Part 11 compliance requirements, ensuring traceability and audit-ready documentation.
Cell-Based Assays for Vaccine Immunogenicity
In addition to potency testing, Avance Biosciences offers a broad range of cell-based and immunological assays that help evaluate immune responses generated by vaccine candidates. These assays support both preclinical and clinical programs.
Our capabilities include:
- Flow cytometry and immunophenotyping
- FluoroSpot and immune cell activation assays
- Cytokine profiling
- Neutralization and functional immune response assays
These approaches provide critical data for understanding vaccine performance and optimizing immunogenicity.
Supporting Vaccine Innovation
With decades of experience supporting biologics development, Avance Biosciences combines advanced molecular technologies, cell-based assays, and regulatory-ready workflows to help vaccine developers move programs forward with confidence.
Our integrated testing capabilities allow sponsors to work with a single partner for many of the analytical requirements involved in vaccine development, from potency assay development to sequencing-based safety testing.
Meet Avance Biosciences at the World Vaccine Congress
The World Vaccine Congress provides an opportunity for vaccine developers to explore new technologies, build partnerships, and discuss solutions to the challenges of modern vaccine development.
If you are attending the meeting in Washington, DC, we invite you to visit the Avance Biosciences booth to learn more about our vaccine testing capabilities, including potency assays, RNA sequencing, cell-based assays, and NGS safety testing.
Our scientific and business development teams look forward to discussing how we can support your next vaccine program.
When you partner with Avance Biosciences™, you gain a CRO partner that is creative, collaborative and dedicated to sound science with a focus on the regulatory requirements our partners require. Contact our technical staff to discuss how we can support you in your project!
